David Huang, MD, PhD, is a co-inventor of GoCheck Kids™, Gobiquity™’s first mobile health app designed for the early detection of amblyopia risk factors in children. David Huang is also a co-inventor of optical coherence tomography (OCT), a technology that is widely used for refractive surgery and other medical and diagnostic purposes. Dr. Huang was the first author of the seminal article on OCT that was published in Science in 1991, which has been cited more than 3,300 times.
Dr. Huang was previously involved at the Keck School of Medicine at the University of Southern California (USC), where he served as the Manger Chair in corneal laser surgery and as an associate professor of ophthalmology and biomedical engineering. He was also the Director of the Doheny Laser Vision Center at the Doheny Eye Institute, also at USC.
He earned his MD from Harvard Medical School and PhD from Massachusetts Institute of Technology, and completed his ophthalmology residency at USC and cornea fellowship at Emory University. In September 2010, Dr. Huang and his research group, the Center for Ophthalmic Optics and Lasers, joined the renowned Casey Eye Institute at the Oregon Health and Science University where he is currently the Weeks Professor of Ophthalmic Research.
Andrew Burns is an experienced senior executive with a proven ability to lead, build, and operate early stage businesses and drive strategic growth by establishing alliances, overseeing investment rounds, and facilitating mergers and acquisitions.
Prior to joining the Gobiquity™ Mobile Health team, Andrew spent time in the digital healthcare space serving in executive positions for both WorldOne and Epocrates. At WorldOne, where he served as Chief Operating Officer, Andrew successfully launched WorldOne Interactive, a division focused on developing and commercializing a digital health product portfolio to connect and engage healthcare professionals. As the Senior Vice President of Business Development and Strategic Alliances for Epocrates, he helped play a role in the company’s growth from less than $10 million to over $100 million in annual revenue.
Andrew completed his undergraduate education at the University of Western Ontario in Canada and his graduate work at the University of Arizona where he received his MBA in marketing and accounting.
Gil Kliman, MD, joined InterWest's healthcare team in 1996. He invests in a broad array of healthcare opportunities, focusing on medical devices and healthcare IT, with a special interest in ophthalmology. Dr. Kliman has led InterWest's medical device team since 1999 and pioneered InterWest's ophthalmology franchise.
Prior to InterWest, Gil was a healthcare investor at TA Associates and at Norwest Venture Capital. A former practicing ophthalmologist and laser researcher, he was previously West Coast director of LCA Vision, and served as an assistant professor at Tufts New England Eye Center and on the clinical faculty at Massachusetts Eye and Ear Infirmary.
Gil has a BA from Harvard University. He received an MD from the University of Pennsylvania and an MBA from Stanford University. He completed an ophthalmology residency at Wills Eye Institute and retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation Fellow. He also serves as a National Trustee for the Foundation Fighting Blindness. He is a board member of Autonomic Technologies, Benvenue, Doximity, Glaukos, Gobiquity, Restoration Robotics, and ReVision Optics.
Michelle is a recognized marketing and strategy leader in the digital health space, serving in a variety of roles ranging from building early stage companies to advising and investing in them. Michelle is currently the Chief Marketing Officer for Welltok, a leading consumer health enterprise SaaS company, where she leads all corporate marketing activities, including brand development, company and product positioning, marketing communications, and public relations.
Prior to Welltok, Michelle was an Executive-in-Residence for InterWest Partners where she focused on investing and helping portfolio companies in the digital health space. She was also one of the early executives at Epocrates and worked for over a decade to build the company into one of the leading mobile healthcare technology companies and the most recognized technology brand among clinicians.
Prior to Epocrates, she worked as a health strategy consultant with the Wilkerson Group and in health policy formation and implementation with the Lewin Group and the Georgetown Center for Health Policy Studies.
Michelle earned her bachelor’s degree from Carleton College and MBA from Kellogg School of Management at Northwestern University.
John Voris is a seasoned businessman with over 39 years of experience in a variety of executive positions for several well-known and well-respected healthcare companies. He spent the first 27 years of his career at Eli Lilly and Company across a variety of positions in domestic sales and marketing, business development, international business, medical device, and pharmaceutical benefits management.
After retiring from Lilly, he joined Epocrates, a private, venture-backed company that his since gone public (EPOC:Nasdaq), as Chairman and CEO. John remained in this role until 2004 and continued to serve on the board until after its IPO in 2011. In 2005, John became the CEO of HAPC, Inc., a public acquisition company that in 2006 acquired InfuSystem Holdings (INFU:NYSE), an oncology pump and infusion service business, and served on the board until 2012.
John received his BS and MBA from the Kelley School of Business, Indiana University. He is currently the Chairman at Regenesis Biomedical, a private medical device company. He is also an investor in four venture healthcare-focused funds and one private equity fund, is a member of the Dean’s Council at the Kelley School, and serves on the board for Gobiquity.